InspireMD, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $23.9M
- Price
- $0.514
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.13%
- Volume
- 145.2K
About
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
Quick stats
Shares outstanding46.5M
Computed float31.5M
Float / shares67.7%
Cash runway (months)5.1
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001433607
Websitehttps://www.inspiremd.com
AI Summary
AI-generated1/19
standardmixeddilution
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
InspireMD amended its Series J and Series K warrants from the May 2023 private placement to align potential exercise with the anticipated Q4 2026 FDA approval of CGuard Prime 80 cm for TCAR procedures, with potential gross proceeds of up to $11 million.
The amended $0.7674 exercise price — the Nasdaq Official Closing Price on September 18, 2026 — applies to half of the roughly 4.8 million underlying Series J shares and all 9.5 million underlying Series K shares, with termination extended to the earlier of May 15, 2028 or 20 trading days after an FDA approval announcement; the remaining Series J shares keep their $1.3827 strike and no additional warrants were issued.
CGuard Prime 80 cm targets the estimated 35,000-plus annual U.S. TCAR procedures, which the company says would double its U.S. addressable market, supported by CGUARDIANS II pivotal data showing 100% acute device success and zero major adverse events at 30 days in the first 36 patients.
Proceeds, combined with existing cash, are earmarked for the TCAR launch and pipeline priorities, but the release reiterates substantial doubt about the company's ability to continue as a going concern and ongoing exposure from the voluntary recall of the CGuard Prime 135 cm delivery system.
Red flags
- Warrant exercise price cut to $0.7674 from the original $1.3827 Series J strike — dilutive repricing to near-market to induce exercise
- Forward-looking statements disclose substantial doubt regarding ability to continue as a going concern and a history of recurring losses
- Ongoing voluntary U.S. recall of CGuard Prime 135 cm delivery system with potential refund, inventory write-off and product-liability litigation exposure
- Proceeds are contingent on warrant holders electing to exercise; the 'up to $11 million' figure is not assured
- FDA approval of CGuard Prime 80 cm is anticipated, not granted — trigger timing and associated exercises may slip